Biomedical Catalyst - Early Stage

Objectives and Scope

The BMC aims to support the development of innovative healthcare products, technologies and processes. Such solutions can include (but are not limited to) those focused on:

  • disease prevention and proactive management of health and chronic conditions;
  • earlier and better detection and diagnosis of disease, leading to better patient outcomes;
  • treatments that either change underlying disease or offer potential cures).

The aim of Early and Late Stage awards is to create a data package that is sufficient to support the subsequent testing of products or process in a clinical setting or other relevant environment. 

Support is available for any life science sector or discipline, including (but not limited to):

  • medical technologies and devices;
  • stratified healthcare;
  • advanced therapies (gene and cell therapies);
  • digital health;
  • drug discovery;
  • diagnostics.
Eligibility and Funding

The total funding allocated to Early and Late Stage awards is £7m.

Projects should have costs of between £250k and £4m, with durations of at least 1 year. All projects must be led by a UK-based SME or RTO, SMEs can work alone or collaborate but RTOs must collaborate with at least 2 SMEs. 

Successful applicants can receive funding:

  • up to 70% of your eligible project costs if you are a micro/small business;
  • up to 60% if you are a medium-sized businesses.

Large organisations are not eligible for funding.

Research organisations can receive up to 100% funding, which is capped at 50% of total eligible project costs and is shared between such organisations if more than one participates.

Key Dates

Applications: noon, 03/04/2019

Invitations to interview: 10/05/2019

Results: 21/06/2019

Ask clarifications to our BIOPEN expert in Horizon2020 and in National and European funding programs